NCT00821574View on ClinicalTrials.gov

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Hypertension, Dyslypidaemia
Interventions
DRUG

Fluvastatin

Fluvastatin: daily 80 mg, oral

DRUG

Valsartan

Valsartan: daily 160 mg, oral

DRUG

Hydrochlorothiazide

Hydrochlorothiazide: daily 12.5mg, oral

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY